Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing a 4,5,6,7-tetrahydrothieno [3,2-c]pyridine as potent EGFR inhibitors.
Li Y, Chang Y, Fu J, Ding R, Zhang L, Liang T, Liu Y, Liu Y, Hu J.
To resolve the problem of drug resistance caused by epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer, we used the principle of collocation to design and synthesize a series of aminopyrimidine derivatives with 4,5,6,7-tetrahydrothieno [3,2-c]pyridine side chains (according to the binding mode of AZD9291 to EGFR<sup>T790M</sup>) for use as EGFR<sup>L858R/T790M</sup> kinase inhibitors. The most promising compound A12, a non-covalently bound reversible inhibitor, showed excellent kinase inhibitory activity against EGFR<sup>L858R/T790M</sup>, with an IC<sub>50</sub> value of 4.0 nM and more than 42-fold selectivity for EGFR<sup>WT</sup> (IC<sub>50</sub> = 170.0 nM). Moreover, compound A12 showed strong anti-proliferative activity against H1975 cells, with IC<sub>50</sub> value of 0.086 μΜ. Additionally, the effective inhibition of cell migration and the promotion of apoptosis by A12 verified its mechanism of action, as a selective inhibitor of EGFR<sup>L858R/T790M</sup>.